Phase I-II Study of Intraoperative Radiation Therapy (IORT) After Radical Prostatectomy for Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 4, 2008, Pages 1049-1056

  Saracino, Biancamaria ^a   Gallucci, Michele ^a   De Carli, Piero ^a   Soriani, Antonella ^a   Papalia, Rocco ^b   Marzi, Simona ^a   Landoni, Valeria ^a   Petrongari, Maria Grazia ^a   Arcangeli, Stefano ^a   Forastiere, Ester ^a   Sentinelli, Steno ^a   Arcangeli, Giorgio ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

ratio; Intraoperative radiotherapy; Prostate cancer; Radical prostatectomy

Indexed keywords

BIOCHEMICAL ENGINEERING; DOSIMETRY; ELECTROTHERAPEUTICS; IRRADIATION; MICROFLUIDICS; PEELING; PIGMENTS; RADIATION; RISK PERCEPTION;

CONVENTIONAL FRACTIONATION (CF); DOSE LEVELS; ELSEVIER (CO); GLEASON SCORE (GS); INTRAOPERATIVE RADIATION THERAPY (IORT); INTRAOPERATIVE RADIOTHERAPY (IORT); LOCALIZED PROSTATE CANCER; LYMPH NODE METASTASES; NORMAL TISSUES; PHASE I; PROGRESSION FREE SURVIVAL; PROSTATE CANCER (CAP); PROSTATE SPECIFIC ANTIGEN (PSA); RADIATION FIELDS; RADICAL PROSTATECTOMY (RP); RISK FACTORS; TUMOR BED;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FOLLOW UP; FRACTIONATION; GLEASON SCORE; HUMAN; INTRAOPERATIVE RADIOTHERAPY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION FIELD; RISK FACTOR; SURVIVAL RATE;

AGED; FEASIBILITY STUDIES; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 45449097645     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.11.076     Document Type: Article

References (25)

1. Han M., Partin A.W., Zahurak M., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523
2. Kupelian P., Katcher J., Levin H., et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 3 (1997) 70
3. Porter C.R., Kodama K., Gibbons R.P., et al. 25-year prostate cancer control and survival outcomes: A 40-year radical prostatectomy single institution series. Clinical significance and therapeutic implications. J Urol 176 (2006) 569-574
4. Carver B.S., Bianco F.J., Scardino P.T., et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176 (2006) 564-568
5. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172 (2004) 910-914
6. Kupelian P.A., Katcher J., Levin H.S., et al. Stage 1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37 (1997) 1043-1052
7. Connolly J.A., Shinohara K., Presti Jr. J.C., et al. Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47 (1996) 225-231
8. D'Amico A.V., Chen M.H., Catalona W.J., et al. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110 (2007) 56-61
9. Tolleffson M.K., Slezak J.M., Leibovich B.C., et al. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clinic Proc 82 (2007) 422-427
10. Rosen M.A., Goldstone L., Lapin S., et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148 (1992) 331-337
11. Lowe B.A., and Lieberman S.F. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: Selecting the patient for adjuvant therapy. J Urol 158 (1997) 1452-1456
12. Schild S.E. Radiation therapy after prostatectomy: Now or later. Semin Radiat Oncol 8 (1998) 132-139
13. Morris M.M., Dallow K.C., Zietman A.L., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 38 (1997) 731-736
14. Bolla M., Von Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
15. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
16. Kupelian P.A., Reddy C.A., Willoughby P.R., et al. Preliminary observations on biochemical relapse-free survival rates after short course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 53 (2002) 904-912
17. Fowler J.F., Chappell R.J., and Ritter M.A. The prospects for new treatments for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 3
18. Yeoh E.E., Holloway R.H., Frases R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (2006) 1072-1083
19. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
20. Amer A.M., Mott J., Mackay R.I., et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 56 (2003) 199-207
21. King C.R., and Fowler J.F. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys 51 (2001) 213
22. Fowler J.F., Chappell R.J., and Ritter M.A. Is α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
23. Jones B., Dale R.G., Deehan C., et al. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) 13 (2001) 71-81
24. Soriani A., Landoni V., Marzi S., et al. Setup verification and in vivo dosimetry during intraoperative radiation therapy (IORT) for prostate cancer. Med Phys 34 (2007) 3205-3210
25. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346